Theses›Healthcare & bio›Biocomputing

Biocomputing

Living-neuron / organoid biocomputing is a real and accelerating research field, but as an investment it does not clear the gate today.

  • Bear
  • Early
  • $11B by 2035

The callRestraints win: nobody pays for compute on neurons, and organoids die past half a millimetre without a blood supply. A research field, early by a decade.

D1D2R1R2C1foragainst D1D2R1R2C1foragainst
Fig. 1The balance. Drivers and catalysts against restraints, each block sized by its weight; catalysts hang dashed because they have not happened yet, sized by their odds. It tips toward the restraints.
  1. D1AI's energy bill becomes the limit, datacentre electricity roughly doubling to about 945 TWh by 2030, while a brain learns from a handful of examples on a fraction of that.
  2. D2Programme money is arriving, NSF's $14M across 7 teams and an EIC grant, though the growth number here assumes it grows about 10x.
  3. R1Nobody pays for compute on neurons, and silicon, photonics and neuromorphic chips get the AI-energy money first.
  4. R2Organoids die past 300-500 micrometres without perfusion, and nothing solves scale, lifespan and reproducible training together.
  5. C1A peer-reviewed organoid over 1mm keeps a living interior for 6 months, the blood-supply step everything else waits on; Frontier Computing raised $10M early on that claim.end-2027
Rests onthe beliefs underneath
Supported by · confidence
What would prove itdated tests, open and resolved
202720282029today123predictionswatch 202720282029today123predictionswatch
Fig. 2Each ring is a dated test: dashed while open, struck through when overdue, ticked or crossed once resolved.
  1. 1Vascularisation/scale stays unsolved: no peer-reviewed organoid >1 mm with a viable (non-necrotic) interior sustained >6 months by end-2027.Dec 2027 · open
  2. 2By end-2028 no living-neuron/organoid company will book recurring commercial revenue for a COMPUTE task.Dec 2028 · open
  3. 3Any company books recurring compute revenue from a workload that beats silicon on something customers pay for.Dec 2028 · open
Expressionslisted, private, technologies
  • HBIOHarvard Bioscience (Multi Channel Systems)
    • not screened
     In-vitro and in-vivo microelectrode-array electrophysiology systems through its Multi Channel Systems unit, sold to research labs.
  • MRK.DEMerck KGaA (HUB Organoids)
    • full
     Patient-derived organoid models and organoid drug-discovery services, sold to pharma, after buying HUB Organoids.
  • TMOThermo Fisher Scientific
    • full
     Stem-cell media, reagents and culture tools used to grow neurons and organoids, sold to pharma and academic labs.
Private · 7 private companies, 3 of them in the US.

Parasma · Frontier Computing · Cortical Labs · FinalSpark · Koniku · The Biological Computing Co. · MaxWell Biosystems

1 more private company tracked, not shown

Technologies
Who has already bet on itprivate rounds, from public sources

$87M raised by 6 companies, $35M of it in the last three years. Wave building: Money is arriving: recent rounds and tier-1 funds are in, but no runaway leader yet.

Backed by a top-tier venture firm: Koniku, Frontier Computing, Parasma. Backed by a strategic investor: Koniku.

  • $37MKoniku
    • Founded 2015
     Series A, Dec 2021 $37M (Presight Capital, SoftBank Vision Fund, Airbus Ventures)
  • $25MThe Biological Computing Co.
    • Founded 2022
     Seed, Feb 2026 $25M (Primary Ventures, Builders VC, Refactor Capital)
  • $10MCortical Labs
    • Founded 2019
     Funding round, Apr 2023 $10M (Horizons Ventures, Blackbird Ventures, LifeX Ventures)
  • $10MFrontier Computing Pre-seed, Sep 2026 $10M (General Catalyst, LocalGlobe, Amino Collective)
  • $5MMaxWell Biosystems
    • Founded 2016
     Series A, Dec 2020 $5M (Sensirion, Venture Kick, existing shareholders and business angels)
  • ·Parasma
    • Founded 2026
     Accelerator (YC S26), 2026 (Y Combinator)
What changedthe record, newest first
  • 7 Oct 2026Biocomputing is now a Y Combinator category, with two companies in one batch. The money is moving faster than the science: still no customer paying for compute on living neurons.
  • 3 Jun 2026Biological computing is having a press moment, but the honest read is the science is a decade out, no one has a paying compute customer, and the durable money so far is in the picks-and-shovels (electrode-array hardware), not the living cells.
Reading
Show the reading